Welcome to our dedicated page for Rocket Pharmaceu news (Ticker: RCKT), a resource for investors and traders seeking the latest updates and insights on Rocket Pharmaceu stock.
Rocket Pharmaceuticals, Inc. reports developments in rare-disease genetic medicines, including its commercial-stage therapy KRESLADI for pediatric patients with severe leukocyte adhesion deficiency-I and its broader pipeline of investigational gene therapies. Company updates commonly address FDA actions, clinical-program progress, regulatory submissions, and financial results tied to research, development, and commercial readiness.
Recurring news themes include the AAV cardiovascular portfolio, such as RP-A501 for Danon disease, RP-A601 for PKP2-arrhythmogenic cardiomyopathy, and RP-A701 for BAG3-related dilated cardiomyopathy. Rocket also reports capital and balance-sheet actions, including monetization of its Rare Pediatric Disease Priority Review Voucher, as well as presentations at healthcare conferences.
Rocket Pharmaceuticals (NASDAQ: RCKT) reported Q3 2025 results and program updates on November 6, 2025. Cash, cash equivalents and investments were $222.8M, which the company expects will fund operations into the second quarter of 2027 (excluding any Priority Review Voucher proceeds).
Regulatory and clinical milestones include FDA acceptance of a resubmitted BLA for KRESLADI with a PDUFA date of March 28, 2026, FDA agreement to resume the pivotal Phase 2 trial of RP-A501 for Danon disease with three additional patients dosed at 3.8×10^13 GC/kg in 1H 2026, and ongoing development of RP-A601 and RP-A701. Leadership additions were announced for CMO, COO, and Chief Commercial & Medical Affairs.
Rocket Pharmaceuticals (NASDAQ: RCKT) announced the FDA has accepted the resubmission of the Biologics License Application for KRESLADI™ (marnetegragene autotemcel) for severe Leukocyte Adhesion Deficiency-I (LAD-I).
The Prescription Drug User Fee Act (PDUFA) target action date is March 28, 2026. The BLA is supported by global Phase 1/2 data showing 100% overall survival at 12 months, met all primary and secondary endpoints, demonstrated reductions in significant infections, improvement in skin lesions and wound healing, and was well tolerated with no treatment-related serious adverse events. Rocket is eligible for a Rare Pediatric Disease Priority Review Voucher if approved.
Rocket Pharmaceuticals (NASDAQ: RCKT) said on October 6, 2025 its Compensation Committee approved inducement equity awards for new Chief Medical Officer Dr. Syed Rizvi as a hiring incentive under Nasdaq Rule 5635(c)(4).
The grants include a nonstatutory stock option to buy 383,854 shares (10-year term, exercise price = Nasdaq close on Oct 6, 2025), 283,018 restricted stock units (On-Hire RSUs) and 62,893 additional RSUs. Vesting: the option and On-Hire RSUs vest 1/3 at one year then quarterly over two years; Additional RSUs vest 50% at one year and 50% one year later. Grants were approved as a material inducement to employment.
Rocket Pharmaceuticals (NASDAQ: RCKT), a late-stage biotechnology company focused on genetic therapies for rare disorders, has announced its participation in two major healthcare conferences in September 2025.
CEO Gaurav Shah, M.D. will participate in fireside chats at the 2025 Cantor Fitzgerald Global Healthcare Conference on September 3 at 3:20 PM ET and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9 at 9:15 AM ET. Management will also host investor meetings at both events. Webcasts will be available on the company's investor relations website.
Rocket Pharmaceuticals (NASDAQ:RCKT) announced the FDA has lifted the clinical hold on its pivotal Phase 2 trial of RP-A501 for Danon disease treatment in under three months. The trial will resume with a recalibrated lower dose of 3.8 x 10¹³ GC/kg in three patients, treated sequentially with four-week intervals.
The modified protocol includes an adjusted immunomodulatory regimen similar to the Phase 1 pediatric cohort, removing prophylactic C3 complement inhibitor while maintaining other components. Six patients have been treated to date in the Phase 2 study. The trial's co-primary endpoints include LAMP2 protein expression improvements and left ventricular mass reductions, with troponin change as a key secondary endpoint.
Rocket Pharmaceuticals (NASDAQ: RCKT) reported Q2 2025 financial results and strategic updates, highlighting a significant organizational restructuring and pipeline prioritization. The company is focusing on its AAV cardiovascular gene therapy platform, particularly RP-A501 for Danon disease, RP-A601 for PKP2-ACM, and RP-A701 for BAG3-DCM.
Key financial metrics include cash position of $271.5M with runway into Q2 2027, Q2 R&D expenses of $42.7M (down from $46.3M YoY), and net loss of $68.9M ($0.62 per share). The company announced a 30% workforce reduction expected to lower 12-month cash burn by nearly 25%.
Notable developments include FDA RMAT designation for RP-A601, Fast Track designation for RP-A701, and ongoing FDA review of KRESLADI™ for LAD-I treatment. The RP-A501 Danon disease trial remains on clinical hold following a serious adverse event.
Rocket Pharmaceuticals (NASDAQ: RCKT) announced a strategic corporate reorganization focusing on its AAV cardiovascular platform and KRESLADI™ regulatory activities. The restructuring includes a 30% workforce reduction and aims to lower 12-month cash burn by 25%.
The company will prioritize its cardiovascular programs targeting Danon disease, PKP2-ACM, and BAG3-DCM, which collectively address over 100,000 patients in the U.S. and EU. The reorganization extends Rocket's cash runway into Q2 2027 and delays development of Fanconi Anemia (FA) and Pyruvate Kinase Deficiency (PKD) programs, with FDA approval for RP-L102 no longer expected in 2026.
Rocket Pharmaceuticals (NASDAQ: RCKT) has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for RP-A601, its gene therapy treatment for PKP2-arrhythmogenic cardiomyopathy (ACM). This marks the company's fifth RMAT designation.
The designation was granted based on positive Phase 1 clinical trial results where all three adult patients treated with RP-A601 showed increased PKP2 protein expression, with two patients experiencing increases of 110% and 398%. Patients demonstrated improved desmosomal integrity and clinical benefits including enhanced right ventricular function and quality of life, with KCCQ-12 scores increasing by 34-41 points.
The RMAT designation provides benefits including intensive FDA guidance, expedited review, and potential accelerated approval pathways for this treatment of life-threatening heart failure disease.
Rocket Pharmaceuticals (NASDAQ: RCKT) has received FDA clearance for its Investigational New Drug (IND) application for RP-A701, a novel gene therapy candidate targeting BAG3-associated Dilated Cardiomyopathy (BAG3-DCM). This marks the company's third clinical-stage gene therapy candidate in its AAV cardiovascular portfolio.
The upcoming Phase 1 clinical trial will be a multi-center, dose-escalation study evaluating RP-A701's safety, biological activity, and preliminary efficacy in adult patients with BAG3-DCM. The trial will focus on adults with implantable cardioverter defibrillators (ICDs) and advanced disease who are at high risk for heart failure progression and cardiac death.
BAG3-DCM is characterized as a rare, inherited heart condition caused by BAG3 gene mutations, resulting in early-onset, progressive heart failure with high morbidity and premature mortality. The study will assess BAG3 protein expression, changes in cardiac biomarkers, and clinical predictors of disease progression.